Novartis AG (NVS) recently announced new long-term data from an extended phase III head-to-head TRANSFORMS study, which evaluated its multiple sclerosis (MS) candidate Gilenya (fingolimod). The ...
via Investopedia.com Headlines http://www.investopedia.com/stock-analysis/Zacks/NovartisPresentsDataonGilenya-AnalystBlog.aspx
8233 Old Courthouse Rd Ste 330 Vienna V.A. 22182
Matt Sileno
The Intuitive Group Inc
No comments:
Post a Comment